---
title: 'Senior Scientist II, Upstream Process Development and MSAT at Scholar Rock'
canonical: 'https://feeny.ai/job/senior-scientist-ii-upstream-process-development-and-msat-scholar-rock-cambridge-95jr4cxt29by'
type: 'job'
last_seen: '2026-11-08'
---

# Senior Scientist II, Upstream Process Development and MSAT at Scholar Rock

- **Company:** Scholar Rock
- **Location:** Cambridge, MA
- **Compensation:** $155k–$195k
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-11-02
- **Last confirmed live:** 2026-11-08
- **Apply:** https://jobs.lever.co/scholarrock/11f6ee81-8a0a-4d6c-bcd5-fbc7e912e7a0

## Job description

Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Summary of Position:

Position Responsibilities

- Drive upstream process development activities for early- and late-stage biologics programs, including cell culture process experimental design, media and feed optimization, and bioreactor process characterization.  Execute in-lab as needed and present data and recommendations to inform development direction to leadership.
- Provide guidance for upstream scale-up, technology transfer, manufacturability assessments and validation activities across external manufacturing sites
- Serve as a subject matter expert for external upstream process development activities, including collaborating with external CDMOs to design robust and technically sound experiments to progress Scholar Rock’s development pipeline
- Serve as a subject matter expert for internal upstream process development activities.  Collaborate cross-functionally with Research, Analytical Development, Quality, Regulatory Affairs, and Downstream Process Development teams to advance programs from early development through commercialization
- Support research, downstream process development, and assay development as needed
- Design experiments and draft protocols to support critical manufacturing deviations and investigations, including internal experimental execution and studies designed for external CMO execution; support the development and implementation of future internal high-throughput bioreactor capabilities, such as AMBR.
- Review manufacturing documents and troubleshoot outsourced manufacturing processes as needed
- Support clinical and commercial GMP manufacturing with person-in-plant activities
- Author upstream technical reports to enable program stage progression and robust regulatory filing input

Candidate Requirements

- Educational background in Chemical Engineering, Biochemistry, Biotechnology, or related biological Sciences
- Experience in DOE, QBD development, process characterization and process validation exercises highly desired
- Direct experience working with mAbs and CHO cell culture is preferred
- BS or MS with 10+ years of experience, Ph.D. with 5+ years of experience
- Experience with Ambr 15/250 high throughput cell culture desired
- Experience with tech transfer to manufacturing preferred
- Cell line development experience is a plus
- Strong attention to detail and experience in summarizing and presenting results to leadership is required
- Some travel required (person-in-plant)

Scholar Rock is an Equal Opportunity Employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

## About Scholar Rock

## Company Overview
- **One-liner**: Scholar Rock is a biopharmaceutical company discovering and developing selective therapies targeting growth factors for serious diseases with high unmet need.
- **Entity Type**: Public (NASDAQ: SRRK)
- **Headquarters**: Cambridge, Massachusetts, United States
- **Founded**: 2012
- **Founders**: Not publicly available

## Core Business
- **Primary industry**: Biotechnology / Biopharmaceuticals
- **Target customers**: Patients suffering from neuromuscular disorders, cancer, fibrotic diseases, and hematologic conditions; healthcare providers and payers
- **Mission**: “Turning scientific discoveries into a pipeline of investigational therapies aimed at diseases where growth factors play a central role.”

## Products & Services
- **Apitegromab (SRK-015)**: A selective anti‑latent myostatin antibody in Phase 3 for spinal muscular atrophy (SMA). BLA resubmission and U.S. launch anticipated in 2026.
- **SRK‑181**: A selective anti‑latent TGFβ1 antibody for locally advanced or metastatic solid tumors (immuno‑oncology).
- **SRK‑373**: A context‑dependent anti‑latent TGFβ1 antibody for multiple fibrotic indications.
- **SRK‑256**: A selective anti‑RGMc/HJV antibody for hematology indications.
- **Proprietary Platform**: Broad technology for generating monoclonal antibodies that selectively target latent forms of growth factors (TGFβ superfamily).

## Market Standing
- **Valuation/Market Cap**: $2.8 B (as of search date, 2026‑09‑06)
- **Key Metric**: Annual revenue $0 (pre‑commercial); IPO in 2018
- **Notable Investors/Partners**: Not publicly available
- **Growth Signals**: Headcount grew 27.4% YoY to 278 employees; workforce across 7 countries; 20,522 LinkedIn followers (+45.9% yearly); first company to show clinical proof‑of‑concept for a muscle‑targeted treatment in SMA.

## Competitive Advantages
- First‑in‑class platform for selectively targeting latent growth factors (TGFβ superfamily), enabling high specificity and reduced off‑target effects.
- Proven clinical proof‑of‑concept in SMA with apitegromab, a novel mechanism.
- Broad pipeline spanning neuromuscular, oncology, fibrosis, and hematology, with multiple programs in Phase 2/3.

## Strategic Focus
- Advance apitegromab toward regulatory submission and commercial launch in SMA.
- Expand pipeline into cardiometabolic disorders and other growth‑factor‑driven diseases.
- Leverage platform to address historically under‑addressed disease areas.

## Why Work Here
- **Culture**: “Passion for science” and “every voice counts” – a collaborative, trust‑based environment focused on changing patients’ lives.
- **Work Policy**: Hybrid (e.g., Senior Director, Business Analytics in Cambridge, MA) and on‑site roles available.
- **Benefits**: Competitive health/dental/vision plans, life/AD&D insurance, short‑ and long‑term disability, paid parental leave, 401(k) match, financial wellness program, professional development, free parking/transit pass, onsite fitness center, weekly community lunches, peer‑to‑peer recognition.
- **Engineering/Science Culture**: Emphasis on innovation, cross‑functional teamwork, and direct impact on serious diseases.

## Sources
1. [scholarrock.com – Company Overview](https://scholarrock.com/our-company/careers/)
2. [scholarrock.com – Investors & Media](https://scholarrock.com/investors-media/)
3. [scholarrock.com – Pipeline](https://scholarrock.com/our-pipeline/)
4. [jobs.lever.co/scholarrock – Open Positions](https://jobs.lever.co/scholarrock)
5. [linkedin.com/company/scholar-rock – Company Profile](https://linkedin.com/company/scholar-rock)

## Other roles at Scholar Rock

- [Director, Learning & Development, EMEA](https://feeny.ai/job/director-learning-development-emea-scholar-rock-zug-rhncqzbktf34) — Zug, Switzerland
- [Director/Senior Director Medical Affairs EMEA](https://feeny.ai/job/director-senior-director-medical-affairs-emea-scholar-rock-zug-p9bcxh80qehk) — Zug, Switzerland
- [Associate Director, Medical Communications, EMEA](https://feeny.ai/job/associate-director-medical-communications-emea-scholar-rock-zug-s0j9z07w5sxe) — Zug, Switzerland
- [Manager/Senior Manager, Medical Information, EMEA](https://feeny.ai/job/manager-senior-manager-medical-information-emea-scholar-rock-zug-5hynwej90da9) — Zug, Switzerland
- [Senior Director, Enterprise Data & Analytics](https://feeny.ai/job/senior-director-enterprise-data-analytics-scholar-rock-cambridge-fd3kyczx97bt) — Cambridge, MA
- [Senior Director / Director, Global Medical Affairs (Evidence Generation)](https://feeny.ai/job/senior-director-director-global-medical-affairs-evidence-generation-scholar-vv3sy40yn3ky) — Cambridge, MA
- [Associate Director, Medical Affairs Operations](https://feeny.ai/job/associate-director-medical-affairs-operations-scholar-rock-cambridge-r70b4ht53zrz) — Cambridge, MA
- [Senior Director, Patient Advocacy & Communications Lead, EMEA](https://feeny.ai/job/senior-director-patient-advocacy-communications-lead-emea-scholar-rock-zug-e7wdbg9mhgqj) — Zug, Switzerland
- [Director, External & CMC Quality Assurance](https://feeny.ai/job/director-external-cmc-quality-assurance-scholar-rock-cambridge-t2bkz2tbxrw6) — Cambridge, MA
- [Director, International Indirect Tax](https://feeny.ai/job/director-international-indirect-tax-scholar-rock-dublin-yat476xmdnaz) — Dublin, Ireland